GNAQ Q209

CI-VAR-00003514Explore in graph →ClinVar 375957 CIViC 507

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Uveal Melanoma2
GNAQ Q209	Refametinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID1233 Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stabl… (full text at CIViC) PMID 23434733 · Weekes et al., 2013 · Open in CIViC	civic
GNAQ Q209	Selumetinib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1213 101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median … (full text at CIViC) PMID 24938562 · Carvajal et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.